PNC-28 Peptide: What Research Actually Shows

PNC-28 is a synthetic 32-amino-acid research peptide built by linking a fragment of the p53 tumor suppressor protein to a cell-penetrating carrier sequence. In laboratory studies, PNC-28 enters cancer cells and triggers rapid cell death, including in cell lines that have lost normal p53 function. PNC-28 is a research chemical only: it is not FDA-approved, has never been tested in human clinical trials, and is not intended for human use.

What Is the PNC-28 Peptide?

PNC-28 was designed as part of an effort to turn the p53 protein into a usable experimental tool. Full-length p53 cannot cross the cell membrane on its own, so researchers trimmed it down to a short fragment and attached a delivery sequence.

• Peptide backbone: residues 361–382 of the human p53 C-terminal domain.
• Delivery sequence: a 10-residue membrane-translocating sequence (MTS) derived from the Antennapedia homeodomain.
• Total length: 32 amino acids.
• Common naming: PNC-28, PNC28, or pnc 28 peptide in catalog listings.

The carrier matters as much as the payload. In published experiments, the p53 fragment alone shows almost no activity in cell culture because it cannot get inside the cell. Adding the membrane-translocating sequence is what makes the compound biologically active, and that combination is what researchers mean by the name PNC-28.

How PNC-28 Works in Cancer Research

PNC-28 does not behave like conventional chemotherapy. It does not need to reach the nucleus, and it does not repair or replace mutated p53.

Preclinical studies suggest the peptide binds to HDM-2, the human form of MDM2, which many tumor cells display on their outer membrane as well as inside the cell. That binding appears to open pores in the cancer cell membrane, causing the cell to swell and rupture. The process is a necrosis-style death that can occur within roughly an hour in cell culture.

Two features make PNC-28 interesting to researchers:

• p53 independence. Cell lines with mutated or deleted p53 still respond, which matters because most human tumors have faulty p53.
• Selectivity in vitro. In several studies, transformed cells died while normal fibroblasts and blood cells were largely unaffected, an effect attributed to higher membrane HDM-2 on cancer cells.

These are laboratory observations. No study has confirmed that PNC-28 kills tumors in humans, and the peptide's behavior in a living organism is far less predictable than in a dish.

What Preclinical Studies Have Reported

The table below summarizes the findings that appear repeatedly in the published PNC-28 literature. All of it comes from cell culture or animal work.

PNC-28 has never been evaluated in a phase 1, phase 2, or phase 3 human trial. There is no established human dose, no pharmacokinetic data, and no evidence of clinical benefit in people.

PNC-28 Compared With Other Research Peptides

PNC-28 sits in a crowded research-peptide market, and it is easy to confuse it with compounds that work in completely different ways. The table below places it next to a few well-known neighbors.

Interest in peptides has expanded well beyond oncology, and searches such as vasoactive intestinal peptide covid and what is semax peptide used for reflect that wider curiosity. A bodybuilding forum user may ask what is ipamorelin peptide, while a mitochondria-focused researcher may want to know where to buy ss-31 peptide. PNC-28 answers a different question entirely: can a fragment of p53 be delivered into a cancer cell to destroy it? So far, that answer exists only in petri dishes and mouse models.

Handling, Reconstitution, and Storage

PNC-28 typically ships as a lyophilized powder and is reconstituted with bacteriostatic water or sterile buffer for in vitro experiments. A peptide dosing calculator is useful for converting the mass printed on the vial into the micromolar concentrations used in cell culture media.

• Store the lyophilized vial at –20 °C, protected from light and moisture.
• Reconstitute gently; avoid vortexing, which can shear the peptide.
• Aliquot the reconstituted solution to limit freeze–thaw cycles.
• Look for a purity specification of 95% or higher by HPLC for reproducible results.

Reported experimental concentrations vary widely between labs, and no standardized protocol exists for PNC-28. Anyone reading a published method should treat those numbers as cell-culture conditions, not as dosing guidance for a person.

Safety, Legal Status, and Sourcing

PNC-28 is not approved by the FDA for any human use, and it is not a dietary supplement. No human safety data exist, and there is no accepted dose, route, or schedule for the compound.

Because the peptide is designed to disrupt cell membranes, injecting it carries obvious theoretical risk, including tissue damage, immune reactions, and infection. Anyone considering any unapproved peptide should consult a licensed healthcare professional rather than rely on forum advice.

For research purchasing, look for a batch-specific certificate of analysis, HPLC purity data, mass spectrometry confirmation, and cold-chain shipping. Vague "99% pure" claims without documentation are a red flag.

The Bottom Line

PNC-28 is an intriguing preclinical tool that combines a short p53 fragment with a cell-penetrating tag to trigger rapid cancer cell death in the lab. PNC-28 is not a treatment, it is not approved for human use, and every published result so far comes from cells or animals.